Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of IV ulimorelin (TZP-101) after partial bowel resection
2011-004474-29Phase 3Terminated
- Sponsor
- Norgine
- Start
- Nov 2011
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative ileus (POI) comparing Ulimorelin IV with Placebo IV (2 arms). Primary endpoint: Safety outcomes (ITT and Safety populations). Started Nov 2011; status: terminated.
02
Drugs
ulimorelin
03
Conditions
postoperative ileus (POI)
Beyond the preview
Go deeper on 2011-004474-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004474-29.